Bioamber (NYSE:BIOA) was downgraded by ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued on Friday.
BIOA has been the topic of several other reports. Cowen reiterated a “hold” rating and set a $1.00 target price on shares of Bioamber in a research note on Friday, November 10th. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Bioamber in a research note on Wednesday, November 8th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. Bioamber currently has a consensus rating of “Hold” and an average price target of $6.50.
Shares of Bioamber (NYSE BIOA) traded down $0.02 on Friday, reaching $0.42. The company’s stock had a trading volume of 938,709 shares, compared to its average volume of 1,356,169. The company has a current ratio of 1.08, a quick ratio of 0.75 and a debt-to-equity ratio of 0.24. Bioamber has a 1-year low of $0.32 and a 1-year high of $6.24.
TRADEMARK VIOLATION NOTICE: This story was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/03/bioamber-bioa-rating-lowered-to-strong-sell-at-valuengine.html.
BioAmber Inc (BioAmber), formerly DNP Green Technology, Inc, is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bioamber Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber Inc and related companies with MarketBeat.com's FREE daily email newsletter.